Check out your Company Bowl for anonymous work chats.
We are thrilled to welcome Franco Marincola, MD, to Kite as Global Head of Cell Therapy Research.
We are proud to announce the opening of our cell therapy manufacturing facility in Europe, bringing CAR T cell therapy production closer to patients in Europe and the surrounding regions. https://bit.ly/3dU3z5K
Our Global Head of Clinical Development Ken Takeshita, MD, shares his perspective on the first virtual ASCO. https://bit.ly/3c479IJ
We at Kite, with the support of Gilead Sciences, are committed to driving cancer research that has the potential to improve the lives of people living with the disease. #WorldCancerDay
CAR T cell immunotherapy named the Advance of the Year in annual ASCO report. We’re proud to play a role in advancing cell therapy: http://glassdoor.com/slink.htm?key=vQssM
How does CAR T cell therapy work?
Kite announces clinical collaboration with Pfizer to evaluate investigational treatment combination in large B-cell lymphoma. Find out more: http://glassdoor.com/slink.htm?key=vQUFB
To support our commitment to bringing our innovative oncology therapies to more people around the world we are hiring. Kite is a fast growing cell therapy specialist with the agility and pace of a start-up but with the support of Gilead’s worldwide infrastructure. Connect today and be a part of our fight against cancer. http://glassdoor.com/slink.htm?key=vQgxz
Looking for an internship opportunity this summer? Kite's parent company Gilead Sciences are hiring at several of their California based sites including their worldwide headquarters in Foster City. Connect via http://glassdoor.com/slink.htm?key=vQgKt to find out more.
Wishing you a happy new year. For 2018, with the support of our parent company Gilead Sciences, we remain committed to bringing our innovative oncology therapies to more people around the world. Follow us to find out more.
